PRESS STATEMENTS

07.09.2012

Ongoing Analyses have Helped Re-evaluate Benefit-Risk Profile of Hormone Therapy for Appropriate Menopausal Women

03.15.2012

Pfizer Response To Ongoing Evaluation Of Hormone Therapy And Breast Cancer, And What It Means For Menopausal Women Who Have Had A Hysterectomy

01.30.2012

Pfizer Joins Innovative Partnership to Eliminate or Control 10 Neglected Tropical Diseases by 2020

11.30.2011

Pfizer Statement Responding to Questions on Voluntary Lipitor Contracting Programs

11.17.2011

Pfizer applauds U.S. Sens. Pat Leahy (VT) and Charles Grassley (IA) and U.S. Reps. Patrick Meehan (PA) and Linda Sanchez (CA) for introducing the "Counterfeit Drug Penalty Enhancement Act of 2011."

11.16.2011

Pfizer announced that the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC)

11.02.2011

Pfizer Responds to Analysis in PLoS One, an Online Publication of the Public Library of Science

10.06.2011

Pfizer Statement Regarding Lyrica Epilepsty

09.08.2011

Pfizer Receives Complete Response Letter From FDA For Moderate-To-Severe Vasomotor Symptoms (VMS) Indication For Pristiq® (desvenlafaxine) Extended Release Tablets.

07.04.2011

Pfizer strongly believes in and supports Chantix as an important treatment option.

06.23.2011

Pfizer Inc. has received the European Commission Decision to renew the marketing authorization (MA) for Champix® (varenicline tartrate) for a further five year period for the treatment of smoking cessation in adults.

06.16.2011

Pfizer has studied Chantix (varenicline) in a randomized, double-blind, placebo-controlled clinical trial in smokers with certain types of cardiovascular disease.

06.08.2011

Pfizer Inc.ýs Alpharma LLC subsidiary has decided to suspend sales in the United States of 3-Nitro® (Roxarsone), a feed medicine used primarily in poultry production.

05.27.2011

Pfizer takes patient safety and regulatory reporting obligations very seriously. All post-marketing reports of adverse events are reviewed by Pfizer and reported to regulatory agencies, including FDA.

05.18.2011

Pfizer is appalled by the allegations of abuse in Libya. We condemn any misuse of our medicines. Pfizer stopped shipping all products to Libya in February, when sanctions were implemented by the international community. Our thoughts remain with the peopl

04.11.2011

New Guidelines Announce Lyrica® (pregabalin) Capsules CV — Pfizer is proud that Lyrica® (pregabalin) capsules CV, which is an FDA approved treatment indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN)

11.23.2010

Pfizer is not involved in the film's production

04.21.2010

Pfizer Statement on Conducting Clinical Trials in Response to the FDA Letter Dated April 9, 2010